CytRx Corporation (NASDAQ:CYTR), the Los- Angeles based cancer treatment developer has surprisingly come under the scanner for misleading investors. CytRx Corporation (NASDAQ:CYTR) is currently under investigation by Cohen Milstein Sellers & Toll PLLC, to find out if there was intentional misleading by executives and office bearers of the organization. The sections for which the investigations are being conducted are: Sections 10(b), 20(a) of the Securities Exchange Act of 1934. CytRx Corporation (NASDAQ:CYTR) stock opened today at $4.20 and is currently trading at $4.17. The stock showed a positive weekly performance of 14.07%.
Pharmaceutical Partners, Inc. (NASDAQ:CPRX) announced the pricing of its previously announced underwritten public offering of 11,325,000 shares of its common stock at an offering price of $2.21 per share. In connection with the offering, Catalyst has also granted the underwriters a 30-day option to purchase up to an additional 1,698,750 shares of common stock to cover over-allotments, if any. Pharmaceutical Partners, Inc. (NASDAQ:CPRX) stock opened at $2.29, in current trading session and currently is at $2.35, by gaining 6.33%.The 52 week range of $0.45-$3.65. Company’s market capitalization is $127.24 million.
The IsoRay, Inc. (NYSEMKT:ISR) on Apr. 1 announced it will host a booth (#301) at the Annual Meeting of the American Brachytherapy Society (ABS). The annual ABS meeting will take place April 3-5, 2014 in San Diego, California at the Manchester Grand Hyatt. IsoRay CEO Dwight Babcock commented, “IsoRay is pleased to once again participate at the ABS annual meeting. At this venue, thought leaders including Drs. Ron Benoit, Sushil Beriwal and Ryan P. Smith of the University of Pittsburg Medical Center (UPMC), Drs. Bhupesh Parashar and Gabriella Wernicke of Weill Cornell Medical College, and Dr. Brian Moran of the Chicago Prostate Center will be panelists or present their papers documenting their experiences and success in using our products. IsoRay, Inc. (NYSEMKT:ISR) stock is currently trading at $3.20 .The EPS of the stock is -0.13. Company’s market capitalization is $173.05 million.
The Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) on Mar. 31 released the top line results of the 12-month Phase II Imaging trial in Alzheimer’s Disease (“IMAGINE” Trial), based on draft results. Prana’s PBT2 did not meet its primary endpoint of a statistically significant reduction in the levels of beta-amyloid plaques in the brains of prodromal/mild Alzheimer’s disease patients, as measured using PiB-PET Standardized Uptake Value Ratio (SUVR). Whilst there was a reduction in the overall levels of the PiB PET signal in patients treated with PBT2, the results were confounded by an atypical reduction of levels of the PiB PET signal in the placebo group as well.Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) stock opened the session at $2.32, and now is at $2.38. The 52 week range of the PRAN stock remained $2.12-$13.29 and the day range was $2.31-$2.47A.